Literature DB >> 26207006

Survival outcomes for oligometastasis in resected non-small cell lung cancer.

Yoshihisa Shimada1, Hisashi Saji2, Masatoshi Kakihana3, Naohiro Kajiwara3, Tatsuo Ohira3, Norihiko Ikeda3.   

Abstract

BACKGROUND: We investigated the factors associated with post-recurrence survival and the treatment for non-small-cell lung cancer patients with postoperative distant recurrence, especially oligometastasis.
METHODS: We reviewed the data of 272 patients with distant recurrence who underwent resection of non-small-cell lung cancer from January 2000 through December 2011.
RESULTS: The type of distant recurrence was classified as oligometastasis (n = 76, 28%) or polymetastasis (n = 196, 72%). Forty-seven (62%) patients with oligometastasis received local therapy (surgery 5, radiotherapy 9, sequential local and systemic therapy 28, chemoradiotherapy 5). Multivariate analysis revealed older age, non-adenocarcinoma, shorter disease-free interval, no pulmonary metastasis, liver metastases, bone metastases, and polymetastasis had significant associations with unfavorable post-recurrence survival. Subgroup analysis of patients with oligometastasis showed histology and disease-free interval had a great impact on survival. Smoking history and histology were associated with survival in patients with lung oligometastasis, whereas systemic treatment and longer disease-free interval were related to increased post-recurrence survival in those with brain oligometastasis.
CONCLUSIONS: This study showed that an oligometastatic state per se was a significant favorable factor. Optimization of personalized systemic treatment and adding local treatment are important in the management of patients with non-small-cell lung cancer and oligometastasis.
© The Author(s) 2015.

Entities:  

Keywords:  Carcinoma; Disease-free survival; Neoplasm recurrence; Recurrence; Survival; local; non-small-cell lung

Mesh:

Year:  2015        PMID: 26207006     DOI: 10.1177/0218492315596463

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  13 in total

1.  Hepatectomy for oligo-recurrence of non-small cell lung cancer in the liver.

Authors:  Fumitaka Ishige; Wataru Takayama; Satoshi Chiba; Isamu Hoshino; Hidehito Arimitsu; Hiroo Yanagibashi; Yosuke Iwatate
Journal:  Int J Clin Oncol       Date:  2018-03-06       Impact factor: 3.402

Review 2.  Surgical approach in oligometastatic non-small cell lung cancer.

Authors:  Davide Patrini; Nikolaos Panagiotopoulos; Benedetta Bedetti; Sofoklis Mitsos; Roberto Crisci; Piergiorgio Solli; Luca Bertolaccini; Marco Scarci
Journal:  Ann Transl Med       Date:  2018-03

3.  Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.

Authors:  Johannes Schwenck; Hansjoerg Rempp; Gerald Reischl; Stephan Kruck; Arnulf Stenzl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-24       Impact factor: 9.236

4.  Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases.

Authors:  Zhe Wang; Shu-Geng Gao; Qi Xue; Xiao-Tong Guo; Li-Xu Wang; Xin Yu; Yi-Kun Yang; Ju-Wei Mu
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 5.  A practical guide for perioperative smoking cessation.

Authors:  Hiroki Iida; Tetsuya Kai; Michioki Kuri; Kumiko Tanabe; Masashi Nakagawa; Chizuru Yamashita; Hiroshi Yonekura; Mami Iida; Ikuo Fukuda
Journal:  J Anesth       Date:  2022-08-01       Impact factor: 2.931

Review 6.  Surgical management of oligometastatic non-small cell lung cancer.

Authors:  Nuria M Novoa; Gonzalo Varela; Marcelo F Jiménez
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 7.  Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Authors:  Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen
Journal:  J Pers Med       Date:  2016-01-15

8.  Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases.

Authors:  Shuheng Shang; Yi Su; Zhaofeng Zhu; Butuo Li; Meiying Guo; Yiyue Xu; Xindong Sun; Linlin Wang; Jinming Yu
Journal:  Cancer Manag Res       Date:  2018-11-27       Impact factor: 3.989

9.  Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.

Authors:  Zhiwei Sun; Shixia Zhou; Junling Tang; Ting Ye; Jingyuan Li; Doudou Liu; Jian Zhou; Jianyu Wang; H Rosie Xing
Journal:  EBioMedicine       Date:  2018-10-06       Impact factor: 8.143

10.  Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.

Authors:  Han Zhou; Tianzhu Lu; Qiaojuan Guo; Yan Chen; Mengwei Chen; Yansong Chen; Yingying Lin; Chuanben Chen; Liqin Ma; Yun Xu; Shaojun Lin; Jianji Pan
Journal:  Cancer Med       Date:  2020-02-23       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.